国产聚乙二醇化干扰素α治疗HBeAg阳性慢性乙型肝炎患者疗效研究  

Efficacy of pegylated interferon α-2b in the treatment of patients with serum HBeAg positive chronic hepatitis B

作　　者：袁春晖 李春雨[1] 李红丽[2] 赵红娜[2] 王文红[2] 孟庆旭[3] 张中学[4] Yuan Chunhui;Li Chunyu;Li Hongli(Department of Infectious Diseases,252nd Hospital,Baoding 071000,Hebei Province,China)

机构地区：[1]解放军第252医院感染病科,河北省保定市071000 [2]保定市传染病医院肝病科 [3]河北大学附属医院普外科 [4]保定市第一医院重症医学科

出　　处：《实用肝脏病杂志》2019年第3期353-356,共4页Journal of Practical Hepatology

基　　金：河北省自然科学基金资助项目(编号:236512)

摘　　要：目的观察国产聚乙二醇化干扰素α-2b(peg-IFN-α-2b)治疗血清HBe Ag阳性的慢性乙型肝炎(CHB)患者的效果。方法 2015年1月～2017年12月纳入血清HBe Ag阳性的CHB患者500例,被分为A组150例,给予国产peg-IFN-α-2b治疗,和B组350例,给予peg-IFN-α-2a治疗。两组均治疗24～48 w。在治疗结束后,随访24 w。结果治疗前,A组血清HBV DNA定量为(6.1±0.7) lg cps/ml、谷丙转氨酶(ALT)为(81.1±29.8)u/l、体质指数为(22.1±2.9)、血清HBe Ag定量为(3.1±0.6) lg s/co和HBs A定量为(4.4±0.6) IU/ml,与B组的(6.2±0.67) lg cps/ml、(80.7±27.9) U/L、(21.9±2.9)、(3.1±0.1) lg s/co和(4.4±0.5) IU/ml比,差异均无统计学意义(P>0.05);在随访24 w结束时,A组血清ALT复常率为64.0%,血清HBV DNA阴转率为60.0%,与B组的66.9%和62.9%比,差异均无统计学意义(P>0.05);两组不良反应发生率也无显著性相差(P>0.05)。结论应用国产peg-IFN-α-2b治疗血清HBe Ag阳性的CHB患者能获得与peg-IFN-α-2a治疗相似的疗效,但价格便宜,具有临床应用价值。Objectives To investigate the efficacy of domestic pegylated interferonα-2b (peg-IFN-α-2b) in treatment of patients with serum HBeAg positive chronic hepatitis B(CHB). Methods 500 patients with serum HBeAg positive CHB were recruited in this study between January 2015 and December 2017,and 150 patients in group A were treated by domestic peg-IFN-α-2b,and 350 patients in group B received peg-IFN-α-2a. The regimen lasted for 24 to 48 weeks,and all patients with CHB were followed-up for 24 weeks. Results At presentation,serum HBV DNA loads,serum alanine aminotransferase(ALT) level,body mass index,serum HBeAg and HBsAg levels in group A were (6.1±0.7) lg cps/ml,(81.1±29.8) U/L,(22.1±2.9),(3.1±0.6) lg s/co and (4.4±0.6) IU/ml,without significantly different as compared to(6.2±0.67) lg cps/ml,(80.7±27.9) u/l,(21.9±2.9),(3.1±0.1) lg s/co and (4.4±0.5) IU/ml in group B(P>0.05);at the end of 24 week follow-up,serum ALT normalization rate and serum HBV DNA loss in group A were 64.0% and 60.0%,also no significantly different as compared to 66.9% and 62.9% in group B(P>0.05);the side effects during the antiviral treatment in the two groups were not significantly different(P>0.05). Conclusion The application of domestic peg-IFN-α-2b in treatment of patients with serum HBeAg-positive CHB might get the same viralogic and biochemical responses,and the regimen is safe and cheap,which warrants further clinical investigation.

关 键 词：慢性乙型肝炎 聚乙二醇干扰素Α-2B HBEAG阳性 疗效 

分 类 号：R512.62[医药卫生—内科学]